High-Tech Gründerfonds (HTGF)

High-Tech Gruenderfonds, headquartered in Bonn and broadly known as HTGF, is the largest seed investor in Germany and one of the most active early-stage backers in Europe. The fund operates as a public-private partnership, drawing capital from the German Federal Ministry for Economic Affairs alongside KfW and a long roster of corporate limited partners spanning industrials, pharma, chemicals, and technology. For founders building healthcare AI in or around the German-speaking world, HTGF is often the first institutional check available, and that ubiquity gives it a particular weight in the local ecosystem.

The fund’s healthcare thesis spans biotech, medical devices, and diagnostics, with a growing tilt toward digital health and AI-enabled platforms that touch clinical workflows. HTGF tends to favor teams with serious technical depth, often spinning out of universities, Fraunhofer institutes, Max Planck centers, or hospital research groups. Its portfolio reflects that pipeline orientation, with strong representation from molecular diagnostics, imaging, lab automation, and software embedded in regulated medical settings. AI-focused founders typically find a home here when the underlying problem is genuinely scientific or hardware-coupled rather than pure SaaS.

HTGF writes initial checks in the $250k to $1M range and reserves significant follow-on capital across subsequent rounds, which matters because life science timelines rarely cooperate with neat 18-month milestones. Geography is principally Germany, but the fund regularly co-invests with European and US firms when the company has international ambitions from day one. Founders should expect a structured process with technical due diligence handled seriously, including external scientific reviewers when appropriate, and standard German seed terms rather than the looser Silicon Valley templates.

The team is large by VC standards, organized into investment leads who specialize by sector. Healthcare and life science partners typically have backgrounds combining doctoral research, industry operating roles, and prior venture experience, and they participate actively on boards through the seed stage and into Series A.

Approaching HTGF works best through warm introductions from portfolio CEOs, university tech transfer offices, accelerator partners, or co-investing angels, though the fund does review qualified inbound submissions. The right time to engage is when a clinical or technical hypothesis has matured to the point of demonstrable proof-of-concept, when key intellectual property is filed or filing is imminent, and when at least one founder is committed full-time. Because HTGF often coordinates with regional grant programs and the EXIST network, founders should arrive with a clear picture of what non-dilutive funding has been secured and what the planned use of seed capital will be over a 24- to 36-month horizon. Decision timelines tend to be measured in months rather than weeks, so this is not the fund to approach when a round must close in a fortnight. It is, however, a strong anchor when the goal is a clean, well-syndicated seed round with a partner who understands German regulatory pathways and the realities of CE-marked medical product development.